Composition for cancer immunotherapy comprising secondary lymphoid organ-derived extracellular vesicle as active ingredient

Abstract

The present disclosure relates to use of a secondary lymphoid organ (SLO)-derived extracellular vesicle (EV) for induction of immune cell activation, induction of ectopic lymphoid structure formation, cancer immunotherapy, and the like. The SLO-derived EV can be provided in a hydrogel formulation to induce formation of ectopic lymphoid structures. The SLO-derived EV may be used together with immune checkpoint inhibitors to exhibit higher anticancer activity by inducing immune cell activation. Furthermore, the SLO-derived EV may exhibit anticancer activity together with immune checkpoint inhibitors in immune checkpoint inhibitor-resistant cancers. Therefore, the SLO-derived EV is expected to be used as an effective anticancer agent or anticancer adjuvant for cancer patients with resistance or tolerance to immune checkpoint inhibitors.

Dependencies are inferred from the claim text.